Sustained investment in cancer research plays a key role in the advancement of molecular oncology and is a major factor driving market progress.
This investment is anticipated to support cutting-edge technologies such as next-generation sequencing, single-cell analysis, and CRISPR/Cas9 gene editing, allowing researchers to unravel the complexities of cancer at the molecular level.
Collaboration between scientists, clinicians, and pharmaceutical companies facilitate the translation of basic research results into clinical applications.
Furthermore, it advances the discovery of novel biomarkers for early detection, prognosis, and monitoring of cancer progression, ultimately leading to improved patient outcomes and survival rates.
Clinical laboratories are increasingly using molecular diagnostics in oncology. Molecular oncology tests are currently being used to evaluate targeted therapy options for colon, lung, breast, ovarian, prostate, multiple myeloma, lymphoma, melanoma, and other cancers.
Multiple techniques, including genomics, computational biology and tumor imaging, as well as in- vitro and in vivo functional models are utilized to understand biological and clinical phenotypes by molecular oncology researchers.
The genes that generate these proteins could be utilized as targets for developing new chemotherapy drugs, cancer treatments, or imaging scans. Molecular oncology uses these combinatorial techniques to validate the role of new candidate genes in cancer development.
| Attribute | Detail |
|---|---|
| Drivers |
|
Advances in cancer treatment have changed the way genetic risks are evaluated and treated. Molecular knowledge can help doctors make better decisions about cancer cure, resulting in more effective treatments.
Demand for advanced medical tools for cancer diagnosis is rapidly increasing as doctors aim to provide individualized care to each patient. Molecular oncology is critical to understanding the insides of cancer cells, helping doctors identify different types of cancer and provide appropriate treatment.
As personalized medicine grows in popularity, the need for better tools will continue to fuel the molecular oncology market size. As more people rely on science rather than guesswork, doctors are increasingly using molecular diagnostics to identify cancer-causing genes and choose the best treatment for each patient.
In the molecular oncology market, tools are essential for different stages of cancer detection and treatment. Instruments are a broad category of products used for genetic analysis, biomarker identification, and tumor feature profiling. Examples of these devices include flow cytometers, PCR devices, and next-generation sequencing (NGS) platforms.
NGS technology is often cutting edge as it can quickly and effectively sequence entire genomes or specific regions of interest, providing important insights into the genetic makeup of tumors. Furthermore, the development of mass spectrometry and digital PCR have greatly contributed to molecular oncology market growth.
Lung cancer is at the forefront of the global molecular oncology market due to its high morbidity and mortality rates, especially in the United States.
In 2024, more than 234,000 new infections and 125,000 deaths are expected, making lung cancer the second most common and deadliest cancer type. Both men and women of all population groups are affected, but the elderly are especially susceptible.
Declining smoking rates and advances in early detection and treatment have reduced the number of infections and deaths. However, lung cancer continues to remain a public health concern.
The underlying relationship between the onset of this disease and smoking is well known; risk factors such as a history of lung disease and occupational factors also influence the onset of this disease. The presence of lung cancer patients necessitates molecular oncology technologies and solutions around the world.
As per the molecular oncology market analysis, Polymerase Chain Reaction (PCR) has the largest share based on technology.
PCR and derivative methods such as reverse transcription PCR and digital PCR have several advantages over traditional techniques such as immunohistochemistry. The main advantage is that it minimizes intra- and interobserver bias due to non-subjective interpretation of results.
Furthermore, interpretation of PCR results does not require an experienced pathologist. This makes PCR easily accessible in many low-resource settings and it is a viable option to use when reliable results are guaranteed. RT-PCR can be performed on fresh frozen tissue, avoiding challenges associated with tissue preparation and fixation.
Additionally, PCR and its derivatives can be automated and standardized across laboratories. This allows for large-scale molecular subtyping of patients. These advantages of PCR have made it a preferred choice for molecular biologists for tumor diagnosis, resulting in it gaining dominant molecular oncology market share worldwide.
In terms of end-user, diagnostic laboratories are crucial in the global molecular oncology market. They help with accurate and fast tests to formulate treatment plans and checking how well treatment is working.
As cancer care becomes more precise, the need for exact tests to guide treatment choices is growing. This shows how important testing labs are in providing good cancer testing and care.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest molecular oncology market forecast, North America is a major player in the landscape. Strong healthcare systems, cutting-edge medical technology, and substantial investment in cancer research and development are driving market dynamics in the region.
The United States, a key player in North America's dominance, is home to top pharmaceutical and biotech companies specializing in molecular oncology diagnostics and treatments.
Additionally, the American Cancer Society offers comprehensive data and analysis on cancer rates, outcomes, and trends, which helps in making well-informed decisions and allocating resources effectively.
Furthermore, North America benefits from a large number of patients, significant healthcare spending, and favorable regulatory policies, all of which offer lucrative molecular oncology market opportunities in the region.
Leading players in the global molecular oncology market are adopting strategies such as development and launch of new products. The molecular oncology industry is fairly competitive with several key players in the mix.
The molecular oncology industry report features profiles of prominent manufacturers, including Roche Diagnostics, Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., and Genomic Health.
Key players have been profiled in the molecular oncology market research report, covering aspects such as company overview, financials, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2023 | US$ 2.3 Bn |
| Forecast (Value) in 2034 | US$ 7.4 Bn |
| Growth Rate (CAGR) | 11.0% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 2.3 Bn in 2023
It is projected to reach more than US$ 7.4 Bn by the end of 2034
The CAGR is anticipated to be 11% from 2024 to 2034
Rise in prevalence of cancer
North America is expected to account for key share during the forecast period
Roche Diagnostics, Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., and Genomic Health, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Molecular Oncology Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Molecular Oncology Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Regulatory Scenario by Region/Globally
5.3. Prevalence of Cancer
5.4. COVID-19 Impact Analysis
6. Global Molecular Oncology Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2020-2034
6.3.1. Instruments
6.3.2. Reagents
6.3.3. Others
6.4. Market Attractiveness By Product
7. Global Molecular Oncology Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2020-2034
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Colorectal Cancer
7.3.4. Ovarian Cancer
7.3.5. Pancreatic Cancer
7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Molecular Oncology Market Analysis and Forecasts, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Technology, 2020-2034
8.3.1. PCR (rt-PCR, d-PCR)
8.3.2. NGS (Next Generation Sequencing)
8.3.3. Microarray
8.3.4. FISH (Fluorescent in situ-hybridization)
8.3.5. Others
8.4. Market Attractiveness By Technology
9. Global Molecular Oncology Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals and Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Cancer Centers and Specialty Clinics
9.3.4. Others (Government and Public Health Agencies)
9.4. Market Attractiveness By End-user
10. Global Molecular Oncology Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Molecular Oncology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2020-2034
11.2.1. Instruments
11.2.2. Reagents
11.2.3. Others
11.3. Market Value Forecast By Application, 2020-2034
11.3.1. Lung Cancer
11.3.2. Breast Cancer
11.3.3. Colorectal Cancer
11.3.4. Ovarian Cancer
11.3.5. Pancreatic Cancer
11.3.6. Others
11.4. Market Value Forecast By Technology, 2020-2034
11.4.1. PCR (rt-PCR, d-PCR)
11.4.2. NGS (Next Generation Sequencing)
11.4.3. Microarray
11.4.4. FISH (Fluorescent in situ-hybridization)
11.4.5. Others
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospitals and Clinics
11.5.2. Diagnostic Laboratories
11.5.3. Cancer Centers and Specialty Clinics
11.5.4. Others (Government and Public Health Agencies)
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Application
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Molecular Oncology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2020-2034
12.2.1. Instruments
12.2.2. Reagents
12.2.3. Others
12.3. Market Value Forecast By Application, 2020-2034
12.3.1. Lung Cancer
12.3.2. Breast Cancer
12.3.3. Colorectal Cancer
12.3.4. Ovarian Cancer
12.3.5. Pancreatic Cancer
12.3.6. Others
12.4. Market Value Forecast By Technology, 2020-2034
12.4.1. PCR (rt-PCR, d-PCR)
12.4.2. NGS (Next Generation Sequencing)
12.4.3. Microarray
12.4.4. FISH (Fluorescent in situ-hybridization)
12.4.5. Others
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospitals and Clinics
12.5.2. Diagnostic Laboratories
12.5.3. Cancer Centers and Specialty Clinics
12.5.4. Others (Government and Public Health Agencies)
12.6. Market Value Forecast By Country, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Application
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Molecular Oncology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2020-2034
13.2.1. Instruments
13.2.2. Reagents
13.2.3. Others
13.3. Market Value Forecast By Application, 2020-2034
13.3.1. Lung Cancer
13.3.2. Breast Cancer
13.3.3. Colorectal Cancer
13.3.4. Ovarian Cancer
13.3.5. Pancreatic Cancer
13.3.6. Others
13.4. Market Value Forecast By Technology, 2020-2034
13.4.1. PCR (rt-PCR, d-PCR)
13.4.2. NGS (Next Generation Sequencing)
13.4.3. Microarray
13.4.4. FISH (Fluorescent in situ-hybridization)
13.4.5. Others
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospitals and Clinics
13.5.2. Diagnostic Laboratories
13.5.3. Cancer Centers and Specialty Clinics
13.5.4. Others (Government and Public Health Agencies)
13.6. Market Value Forecast By Country, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Application
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country
14. Latin America Molecular Oncology Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2020-2034
14.2.1. Instruments
14.2.2. Reagents
14.2.3. Others
14.3. Market Value Forecast By Application, 2020-2034
14.3.1. Lung Cancer
14.3.2. Breast Cancer
14.3.3. Colorectal Cancer
14.3.4. Ovarian Cancer
14.3.5. Pancreatic Cancer
14.3.6. Others
14.4. Market Value Forecast By Technology, 2020-2034
14.4.1. PCR (rt-PCR, d-PCR)
14.4.2. NGS (Next Generation Sequencing)
14.4.3. Microarray
14.4.4. FISH (Fluorescent in situ-hybridization)
14.4.5. Others
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospitals and Clinics
14.5.2. Diagnostic Laboratories
14.5.3. Cancer Centers and Specialty Clinics
14.5.4. Others (Government and Public Health Agencies)
14.6. Market Value Forecast By Country, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Application
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Molecular Oncology Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product, 2020-2034
15.2.1. Instruments
15.2.2. Reagents
15.2.3. Others
15.3. Market Value Forecast By Application, 2020-2034
15.3.1. Lung Cancer
15.3.2. Breast Cancer
15.3.3. Colorectal Cancer
15.3.4. Ovarian Cancer
15.3.5. Pancreatic Cancer
15.3.6. Others
15.4. Market Value Forecast By Technology, 2020-2034
15.4.1. PCR (rt-PCR, d-PCR)
15.4.2. NGS (Next Generation Sequencing)
15.4.3. Microarray
15.4.4. FISH (Fluorescent in situ-hybridization)
15.4.5. Others
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospitals and Clinics
15.5.2. Diagnostic Laboratories
15.5.3. Cancer Centers and Specialty Clinics
15.5.4. Others (Government and Public Health Agencies)
15.6. Market Value Forecast By Country, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Application
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Company Profiles
16.2.1. Thermo Fisher Scientific Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Product Portfolio
16.2.1.3. Financial Overview
16.2.1.4. SWOT Analysis
16.2.1.5. Strategic Overview
16.2.2. Illumina, Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Product Portfolio
16.2.2.3. Financial Overview
16.2.2.4. SWOT Analysis
16.2.2.5. Strategic Overview
16.2.3. Qiagen N.V.
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Product Portfolio
16.2.3.3. Financial Overview
16.2.3.4. SWOT Analysis
16.2.3.5. Strategic Overview
16.2.4. Agilent Technologies, Inc.
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Product Portfolio
16.2.4.3. Financial Overview
16.2.4.4. SWOT Analysis
16.2.4.5. Strategic Overview
16.2.5. Abbott Laboratories
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Product Portfolio
16.2.5.3. Financial Overview
16.2.5.4. SWOT Analysis
16.2.5.5. Strategic Overview
16.2.6. Bio-Rad Laboratories, Inc.
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Product Portfolio
16.2.6.3. Financial Overview
16.2.6.4. SWOT Analysis
16.2.6.5. Strategic Overview
16.2.7. Roche Diagnostics
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Product Portfolio
16.2.7.3. Financial Overview
16.2.7.4. SWOT Analysis
16.2.7.5. Strategic Overview
16.2.8. Genomic Health, Inc.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Product Portfolio
16.2.8.3. Financial Overview
16.2.8.4. SWOT Analysis
16.2.8.5. Strategic Overview
16.2.9. Myriad Genetics, Inc.
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Product Portfolio
16.2.9.3. Financial Overview
16.2.9.4. SWOT Analysis
16.2.9.5. Strategic Overview
List of Tables
Table 01: Global Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 02: Global Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 03: Global Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 04: Global Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 05: Global Molecular Oncology Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 06: North America Molecular Oncology Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 07: North America Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 08: North America Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 09: North America Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 10: North America Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 11: Europe Molecular Oncology Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 13: Europe Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 14: Europe Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 15: Europe Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 18: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 19: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 20: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 21: Latin America Molecular Oncology Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 23: Latin America Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 24: Latin America Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 25: Latin America Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast, by Product, 2020-2034
Table 28: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast, by Cancer Type, 2020-2034
Table 29: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast, by Technology, 2020-2034
Table 30: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Molecular Oncology Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 03: Global Molecular Oncology Market Share Analysis, by Product, 2023
Figure 04: Global Molecular Oncology Market Share Analysis, by Product, 2034
Figure 05: Global Molecular Oncology Market Attractiveness Analysis, by Type, 2024-2034
Figure 06: Global Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 07: Global Molecular Oncology Market Share Analysis, by Cancer Type, 2023
Figure 08: Global Molecular Oncology Market Share Analysis, by Cancer Type, 2034
Figure 09: Global Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 10: Global Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 11: Global Molecular Oncology Market Share Analysis, by Technology, 2023
Figure 12: Global Molecular Oncology Market Share Analysis, by Technology, 2034
Figure 13: Global Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 14: Global Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Molecular Oncology Market Share Analysis, by End-user, 2023
Figure 16: Global Molecular Oncology Market Share Analysis, by End-user, 2034
Figure 17: Global Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Figure 18: Global Molecular Oncology Market Value Share Analysis, by Region, 2023 and 2034
Figure 19: Global Molecular Oncology Market Share Analysis, by Region, 2023
Figure 20: Global Molecular Oncology Market Share Analysis, by Region, 2034
Figure 21: Global Molecular Oncology Market Attractiveness Analysis, by Region, 2023-2034
Figure 22: North America Molecular Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 23: North America Molecular Oncology Market Value Share Analysis, by Country, 2023 and 2034
Figure 24: North America Molecular Oncology Market Attractiveness Analysis, by Country, 2024-2034
Figure 25: North America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 26: North America Molecular Oncology Market Attractiveness Analysis, by Product, 2024-2034
Figure 27: North America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 28: North America Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 29: North America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 30: North America Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 31: North America Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 32: North America Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Molecular Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 34: Europe Molecular Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 35: Europe Molecular Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 36: North America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 37: North America Molecular Oncology Market Attractiveness Analysis, by Product, 2024-2034
Figure 38: Europe Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 39: Europe Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 40: Europe Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 41: Europe Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 42: Europe Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 43: Europe Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Molecular Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 45: Asia Pacific Molecular Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 46: Asia Pacific Molecular Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Asia Pacific Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 48: Asia Pacific Molecular Oncology Market Attractiveness Analysis, by Product, 2024-2034
Figure 49: Asia Pacific Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 50: Asia Pacific Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 51: Asia Pacific Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 52: Asia Pacific Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 53: Asia Pacific Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 54: Asia Pacific Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Figure 55: Latin America Molecular Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 56: Latin America Molecular Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Latin America Molecular Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 58: Latin America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 59: Latin America Molecular Oncology Market Attractiveness Analysis, by Product, 2024-2034
Figure 60: Latin America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 61: Latin America Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 62: Latin America Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 63: Latin America Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 64: Latin America Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 65: Latin America Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 67: Middle East & Africa Molecular Oncology Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Middle East & Africa Molecular Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 69: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Share Analysis, by Product, 2023 and 2034
Figure 70: Middle East & Africa Molecular Oncology Market Attractiveness Analysis, by Product, 2024-2034
Figure 71: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 72: Middle East & Africa Molecular Oncology Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 73: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Share Analysis, by Technology, 2023 and 2034
Figure 74: Middle East & Africa Molecular Oncology Market Attractiveness Analysis, by Technology, 2024-2034
Figure 75: Middle East & Africa Molecular Oncology Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 76: Middle East & Africa Molecular Oncology Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Molecular Oncology Market
